Melanie R Valenti
Overview
Explore the profile of Melanie R Valenti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Faisal A, Mak G, Gurden M, Xavier C, Anderhub S, Innocenti P, et al.
Br J Cancer
. 2017 Mar;
116(9):1166-1176.
PMID: 28334731
Background: The main role of the cell cycle is to enable error-free DNA replication, chromosome segregation and cytokinesis. One of the best characterised checkpoint pathways is the spindle assembly checkpoint,...
2.
Osborne J, Matthews T, McHardy T, Proisy N, Cheung K, Lainchbury M, et al.
J Med Chem
. 2016 May;
59(11):5221-37.
PMID: 27167172
Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic...
3.
Walton M, Eve P, Hayes A, Henley A, Valenti M, de Haven Brandon A, et al.
Oncotarget
. 2015 Aug;
7(3):2329-42.
PMID: 26295308
CCT245737 is the first orally active, clinical development candidate CHK1 inhibitor to be described. The IC50 was 1.4 nM against CHK1 enzyme and it exhibited>1,000-fold selectivity against CHK2 and CDK1....
4.
Lainchbury M, Matthews T, McHardy T, Boxall K, Walton M, Eve P, et al.
J Med Chem
. 2012 Oct;
55(22):10229-40.
PMID: 23082860
Inhibitors of checkpoint kinase 1 (CHK1) are of current interest as potential antitumor agents, but the most advanced inhibitor series reported to date are not orally bioavailable. A novel series...
5.
Walton M, Eve P, Hayes A, Valenti M, de Haven Brandon A, Box G, et al.
Clin Cancer Res
. 2012 Aug;
18(20):5650-61.
PMID: 22929806
Purpose: Many tumors exhibit defective cell-cycle checkpoint control and increased replicative stress. CHK1 is critically involved in the DNA damage response and maintenance of replication fork stability. We have therefore...
6.
Yap T, Walton M, Grimshaw K, Te Poele R, Eve P, Valenti M, et al.
Clin Cancer Res
. 2012 Jul;
18(14):3912-23.
PMID: 22781553
Purpose: Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase is a key driver of multiple cancers. The simultaneous inhibition of multiple...
7.
Witham J, Valenti M, De-Haven-Brandon A, Vidot S, Eccles S, Kaye S, et al.
Clin Cancer Res
. 2007 Dec;
13(23):7191-8.
PMID: 18056200
Purpose: The effective treatment of ovarian cancer is hampered by the development of drug resistance, which may be mediated by members of the Bcl-2 family of apoptosis regulators. ABT-737 is...
8.
Gowan S, Hardcastle A, Hallsworth A, Valenti M, Hunter L, de Haven Brandon A, et al.
Assay Drug Dev Technol
. 2007 Jul;
5(3):391-401.
PMID: 17638539
In this age of molecularly targeted drug discovery, robust techniques are required to measure pharmacodynamic (PD) responses in tumors so that drug exposures can be associated with their effects on...